The shareholders would also be eligible to receive an additional $4 per share contingent (totalling $300m) on regulatory milestones. Image Credit: JHVEPhoto / Shutterstock.

Novartis has acquired Chinook Therapeutics for more than $3.2bn in a move to bolster its portfolio of drugs targeting kidney disease.

With reported sales of $13.62bn in Q2 2023, Novartis is looking to expand its drug portfolio. Just last month, the company acquired DTx Pharma for $1bn for its small interfering RNA (siRNA) treatment portfolio for rare diseases.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of Chinook’s acquisition, its shareholders would receive $40 per share, totalling $3.2bn. The shareholders would also be eligible to receive an additional $4 per share contingent (totalling $300m) on regulatory milestones.

The acquisition comes at a significant inflection point with two high-profile drugs, atrasentan and zigakibart, in Phase III development for the treatment of IgA nephropathy (IgAN). A pivotal data readout for the Phase III atrasentan trial is planned for Q4 2023.

IgAN is a chronic kidney disease, in which immunoglobulin A (IgA) is trapped in the glomeruli of the kidney, thereby causing kidney scarring and damage. As per the charity Kidney Research UK, the current treatment for the disease includes symptomatic control, blood pressure medications that can also reduce proteinuria (a common symptom of IgAN), and immunosuppressants.

Zigakibart is a subcutaneous monoclonal antibody that targets a proliferation-inducing ligand (APRIL). The Phase III trial began in July 2023, with the goal of enrolling 272 participants. The primary endpoint for the study is the change in proteinuria from baseline in the treatment group, compared to a placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Atrasentan is an oral endothelin A receptor antagonist (ERA), which is currently in a placebo-controlled Phase III trial (NCT04573478) for IgAN. Based on available data, Chinook says atrasentan causes a significant reduction in proteinuria compared to placebo.

Chinook’s portfolio also consists of drugs in early phases of development including CHK-336, for treating primary hyperoxaluria (PH) and other kidney stone disorders, its development is on pause due to a serious adverse event observed in its Phase I study.